In Vivo Veritas

If you had $1.9 billion and a Nobel Prize-winning platform, what would you do?

If you’re CRISPR Therapeutics (CRSP), the answer seems to be: launch a drug nobody wants (yet), dilute shareholders with surgical precision, and pivot hard into in vivo editing while biotech newbies panic over cash burn.

Meanwhile, the takeover rumor mill grinds on, as always – because nothing says “due diligence” like speculative blog posts. But underneath the noise, something real is brewing. It just might take longer (and cost more) than Wall Street is willing to admit.

CASGEVY, CRISPR’s first commercial product, was supposed to be the blockbuster debut.

Instead, it’s been a $17 million cameo that left investors wondering whether the sickle cell gene therapy market is as lucrative as PowerPoints once promised. Complexity, reimbursement headwinds, and manufacturing bottlenecks make it a slow, expensive grind.

Vertex (VRTX), CRISPR’s commercial partner, still insists revenue will break nine figures this year and really take off in 2026. But at this point, CASGEVY looks less like a self-funding engine and more like an albatross with a ribbon on it.

That’s pushed investor attention and CRISPR’s own internal firepower toward its in vivo pipeline. The star attraction right now is CTX310, an investigational treatment targeting ANGPTL3 for cardiovascular disease.

The latest Phase 1 data showed a 73% average knockdown of ANGPTL3 at the highest dose, with no dose-limiting toxicities and no signs of off-target effects. This is more than just another lipid-lowering candidate; it’s confirmation that CRISPR’s lipid nanoparticle delivery system works in humans, safely and with high precision.

What makes CTX310 intriguing isn’t just the efficacy. It’s the context. Roughly 40% of the trial patients were already on PCSK9 inhibitors, meaning this new therapy demonstrated additive benefit on top of maximum background therapy.

In other words, we’re not replacing standard-of-care. Instead, we’re building on it. That opens the door to targeting high-risk dyslipidemia subsets where therapeutic headroom still exists.

The idea that CRISPR would chase a broad cardiovascular risk reduction label is premature – and would probably be a strategic blunder. Go niche first, prove durability, and let the risk reduction story emerge organically. This is a marathon, not a meme stock rally.

Financially, CRISPR remains well-armed but dilution-happy. With nearly $2 billion in cash and equivalents, they’ve got the runway to pursue multiple programs. But that runway is paid for in shares – nearly 10% more of them in just nine months.

The company raised $650 million via direct offerings and ATMs since early 2024, and a new $600 million ATM program is now locked and loaded.

Meanwhile, the usual suspects are whispering about a takeover. The Betaville “uncooked” alert stirred the pot, but anyone who understands how M&A actually works knows CRISPR is no easy lift.

You don’t casually acquire a company with multiple unproven programs, a towering cash burn, and no commercial traction. That kind of deal only happens when a buyer is desperate or foolish.

Eli Lilly’s (LLY) acquisition of Verve was an exception, not a trend. More likely, CRISPR will pursue partnerships, particularly in cardiovascular or RNA-based therapeutics, where the validation bar is lower and pharma interest is hotter.

On the pipeline front, the company isn’t just betting on in vivo. The Sirius collaboration on FXI inhibition has advanced into Phase 2, targeting thromboembolic disease with a long-acting siRNA candidate.

And in the alpha-1 antitrypsin deficiency space, CRISPR’s CTX460 has delivered near-total mRNA correction in preclinical mouse models – all with a single dose. First-in-human studies are expected in 2026, and while that feels light-years away in biotech time, these are the kinds of durable, high-value assets that eventually build empires.

As for CAR-T, the company seems content to treat it like a biotech side hustle since it presented no major data, no urgency, and frankly, no clear differentiator.

In an increasingly crowded space, where cell therapy is both capital- and time-intensive, CRISPR’s CAR-T program feels more like optionality than a cornerstone. If cash ever becomes a serious constraint, don’t be surprised if the CAR-T ambitions get quietly trimmed.

What’s left then? A platform company with validated in vivo editing, a slow-burn commercial product, real but early-stage pipeline momentum, and a share count rising faster than a biotech CEO’s conference schedule. This isn’t really a disaster. It’s just the reality in biotech.

We’re not in 2013 anymore, and CRISPR knows it. They’re no longer playing to win the next quarter. They’re playing to own the next decade of genomic medicine.

So if CRISPR’s journey demands more time and more capital, then so be it. After all, breakthroughs worth having rarely come at a discount.